skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

13 Total results for product and free and sample content found

Scrip

Alnylam Seeking Lumasiran Approvals Soon, But Has Two Rivals On Its Heels

By Mandy Jackson 27 Nov 2020

Alnylam_Seeking_Lumasiran_Approvals

Phase III results support early 2020 filings for what could be the RNAi specialist’s third commercial product, but two competing drugs for primary hyperoxaluria from Dicerna and OxThera aren’t far behind. 

Topic Clinical Trials Launches Rare Diseases

Pink Sheet

US FDA's Regulatory Flexibility To Be Tested As Delcath Overhauls Melphalan Trial Design

By Sue Sutter 22 Aug 2018

US FDA's Regulatory Flexibility To Be Tested As Delcath Overhauls Melphalan Trial Design

Accrual difficulties force changes that nullify Special Protocol Assessment; ongoing, randomized FOCUS trial in patients with ocular melanoma that has metastasized to liver will become single-arm study and target enrollment will be reduced by 66%.

Topic Clinical Trials Approvals Rare Diseases FDA

Pink Sheet

Pharma Wants Clarity On Joint Evaluation Of EU Paediatric And Orphan Regulations

By Vibha Sharma 19 Jan 2018

Pharma Wants Clarity On Joint Evaluation Of EU Paediatric And Orphan Regulations

The European Commission's plans to evaluate the EU pediatric and orphan drugs regulation in tandem.

Topic Rare Diseases

Datamonitor Healthcare

Biosimilars in Inflammatory and Autoimmune Disease

11 Oct 2017

Biosimilars Development in Autoimmune and Inflammatory Diseases webinar

Topic Biosimilars Rare Diseases

Scrip

Duchenne Muscular Dystrophy: The Race For The $1bn Opportunity

By Lucie Ellis 03 Oct 2017

Duchenne Muscular Dystrophy: The Race For The $1bn Opportunity

With three products now approved in Europe and/or the US for Duchenne Muscular Dystrophy

Topic Rare Diseases

Pink Sheet

Orphan Biosimilar: Soliris Is One Target

13 Jun 2017

Orphan Biosimilar: Soliris Is One Target

Using lessons learned from the first wave of biosimilar approvals – and citing high prices in the US – some developers are starting to 'think small' with biosimilars for rare disease markets. Alexion’s Soliris is a case in point.

Topic Biosimilars Rare Diseases Research & Development

Pink Sheet

Disease Awareness Campaigns Still Must Tread Carefully, Observer Says

By Mark W. Sherman 03 Jun 2017

Disease Awareness Campaigns Still Must Tread Carefully, Observer Says

Sponsored plotline for General Hospital was careful to avoid irking US FDA; agency withdrew its guidance on disease awareness campaigns in 2015.

Topic Rare Diseases

Pink Sheet

BioMarin's Brineura Approval Shows FDA's Open Door For Orphan Drugs

By Emily Hayes 03 May 2017

BioMarin's Brineura Approval Shows FDA's Open Door For Orphan Drugs

Filing supporting Brineura was supported by a tiny, single-arm study and had no advisory committee review, the latest sign of the US regulatory agency's willingness to speed orphan drugs for serious pediatric diseases.

Topic Rare Diseases

Scrip

Minoryx Preps For Tough Pricing Regime As CNS Orphan Drug Enters Phase II/III

By Lucie Ellis 23 Mar 2017

Minoryx Preps For Tough Pricing Regime As CNS Orphan Drug Enters Phase II/III

Orphan drug development used to be considered a license to print money, with high price tags and a focused customer base. With the development of an increasingly tough orphan drug pricing environment in the US and Europe, biotechs are adopting new strategies. CNS drug developer Minoryx will introduce endpoints into its Phase II/III studies for rare brain disease X-ALD that should help demonstrate both efficacy and value for future pricing discussions.

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: